Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 2 3Phase 1/2 2Phase NA 1Phase 1 1

Status

Terminated 2

Sponsor Class

OTHER 14NIH 3NETWORK 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Glioblastoma 2Neoplasms 1

Interventions

pembrolizumab 242Carboplatin 135Nivolumab 132Gemcitabine 127Paclitaxel 116Cisplatin 105Bevacizumab 95Cyclophosphamide 93Dexamethasone 78Injections 75Docetaxel 72Pemetrexed 71Fluorouracil 68Capecitabine 65Rituximab 61Cetuximab 61atezolizumab 60130-nm albumin-bound paclitaxel 59Oxaliplatin 58Leucovorin 56Ipilimumab 54fludarabine 47Lenalidomide 47Azacitidine 40Irinotecan 39venetoclax 38Fulvestrant 38Albumin-Bound Paclitaxel 36Prednisone 35Trastuzumab 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × INDUSTRY × Carmustine × Clear all
NCT03382977 2026-05-08

Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects

VBI Vaccines Inc.

Phase 1/2 Terminated
70 enrolled
CNS

Glioblastoma, Neoplasms

NCT04421378 2024-12-16

A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma

Karyopharm Therapeutics Inc

Phase 1/2 Terminated
74 enrolled 23 charts
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡